Literature DB >> 20402834

Expression of polycomb protein EZH2 in multi-stage tissues of gastric carcinogenesis.

Gan Hui Cai1, Ke Wang, Qi Miao, Yan Shen Peng, Xiao Yu Chen.   

Abstract

OBJECTIVE: To study the role and significance of the polycomb group (PcG) protein EZH2 (enhancer of zeste homolog 2) in the multi-step process of intestinal-type gastric carcinogenesis.
METHODS: Gastric specimens were obtained from 142 patients with gastric disease, including 34 with chronic non-atrophic gastritis (NCAG), 33 chronic atrophic gastritis (CAG) with intestinal metaplasia (IM), 40 CAG with dysplasia (DYS) and 35 with intestinal-type gastric carcinomas (GC), and 32 Helicobacter pylori-negative controls. The EZH2 protein was stained by the immunohistochemical method and was expressed as the intensity and percentage of the total number of epithelial cells. The chronic gastritis and the grading of dysplasia were classified according to Chinese National Consensus on chronic gastritis and the Padova international classification.
RESULTS: The EZH2 protein levels in the specimens of normal gastric tissue, NCAG, CAG with IM, DYS and intestinal-type GC were gradually increased (P < 0.05), but statistical significance was not found between the groups of DYS and GC.
CONCLUSION: PcG protein EZH2 plays an important role in the multi-step process of intestinal-type gastric carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20402834     DOI: 10.1111/j.1751-2980.2010.00420.x

Source DB:  PubMed          Journal:  J Dig Dis        ISSN: 1751-2972            Impact factor:   2.325


  6 in total

Review 1.  DNA and histone methylation in gastric carcinogenesis.

Authors:  Danielle Queiroz Calcagno; Carolina Oliveira Gigek; Elizabeth Suchi Chen; Rommel Rodriguez Burbano; Marília de Arruda Cardoso Smith
Journal:  World J Gastroenterol       Date:  2013-02-28       Impact factor: 5.742

2.  STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer.

Authors:  Yuan-Ming Pan; Cheng-Gang Wang; Min Zhu; Rui Xing; Jian-Tao Cui; Wen-Mei Li; De-Dong Yu; Shu-Bin Wang; Wei Zhu; Ying-Jiang Ye; Yun Wu; Shan Wang; You-Yong Lu
Journal:  Mol Cancer       Date:  2016-12-09       Impact factor: 27.401

3.  Epigenetics mechanisms mediate the miR-125a/BRMS1 axis to regulate invasion and metastasis in gastric cancer.

Authors:  Jianbo Xiong; Yi Tu; Zongfeng Feng; Daojiang Li; Zhouwen Yang; Qiuxia Huang; Zhengrong Li; Yi Cao; Zhigang Jie
Journal:  Onco Targets Ther       Date:  2019-09-12       Impact factor: 4.147

4.  Integrative Analysis of Deregulated miRNAs Reveals Candidate Molecular Mechanisms Linking H. pylori Infected Peptic Ulcer Disease with Periodontitis.

Authors:  Ning Li; Zhen Wang
Journal:  Dis Markers       Date:  2022-01-29       Impact factor: 3.434

5.  The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy.

Authors:  Natsuki Saigusa; Hideaki Hirai; Yuichiro Tada; Daisuke Kawakita; Masato Nakaguro; Kiyoaki Tsukahara; Satoshi Kano; Hiroyuki Ozawa; Takahito Kondo; Kenji Okami; Takafumi Togashi; Yukiko Sato; Makoto Urano; Manami Kajiwara; Tomotaka Shimura; Chihiro Fushimi; Akira Shimizu; Isaku Okamoto; Takuro Okada; Takayoshi Suzuki; Yorihisa Imanishi; Yoshihiro Watanabe; Akihiro Sakai; Koji Ebisumoto; Yuichiro Sato; Yoshitaka Honma; Keisuke Yamazaki; Yushi Ueki; Toyoyuki Hanazawa; Yuki Saito; Hideaki Takahashi; Mizuo Ando; Shinji Kohsaka; Takashi Matsuki; Toshitaka Nagao
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

6.  The polycomb group protein EZH2 induces epithelial-mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter.

Authors:  Lu Gan; Midie Xu; Ruixi Hua; Cong Tan; Jieyun Zhang; Yiwei Gong; Zhenhua Wu; Weiwei Weng; Weiqi Sheng; Weijian Guo
Journal:  J Hematol Oncol       Date:  2018-01-15       Impact factor: 17.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.